Information Support Activities for Refractory Disease Patient Organizations: The Mitsubishi Tanabe Pharma Tenohira Partnership Program Notice Regarding Determination of Aid Recipients for the Sixth Year(Fiscal 2018)
March 8, 2018
Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka City; President and Representative Director: Masayuki Mitsuka) has announced that it has determined the aid recipients for the sixth year (fiscal 2018) of the Mitsubishi Tanabe Pharma Tenohira Partnership Program. For the sixth year, the program will provide a total of ¥10 million through grants for 21 projects of associations and support groups for patients with refractory diseases (general grants*: 12 projects; small-amount grants*: 9 projects).
- * From the sixth year, the program has started to offer "small-amount grants" to support organizations that have recently started and do not yet have extensive track records of activities.
General grants: More than 3 years of activities, with grant amounts up to ¥1 million
Small-amount grants: More than 1 year of activities, with grant amounts up to ¥300,000
Through the Tenohira Partnership Program, the Company will continue to support patients and their families who are fighting disease, to assist them in finding more joy and satisfaction in their lives, and to help them realize their dreams and hopes for the future.